Visus Therapeutics Inc., a Seattle, WA- Orange County, Calif.-based based clinical-stage pharmaceutical company developing a presbyopia-correcting eye drop, closed a $36m Series A financing.
Backers included Johnson & Johnson Innovation – JJDC, Inc. (JJDC), RTW Investments, LP, and Wille AG, as well as existing shareholders. In conjunction with the funding, Tony Nguyen, managing director at RTW Investments, LP, joined Visus’ board of directors.
The company intends to use the funds to advance the clinical development program for its lead asset, BRIMOCHOL™.
Led by Ben Bergo, co-founder and chief executive officer, Visus Therapeutics is a clinical-stage company in pursuit of developing a presbyopia-correcting eye drop with the potential to last a minimum of eight hours. Its lead clinical candidate is BRIMOCHOL, an eye drop designed to correct the loss of near vision associated with presbyopia. In parallel, Visus Therapeutics is focused on advancing its pipeline of early-stage ophthalmic product candidates.